Bluejay Diagnostics, Inc. Selling and Marketing Expense
Bluejay Diagnostics, Inc. (BJDX) reported Selling and Marketing Expense of $8.30 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-03-06
- Bluejay Diagnostics, Inc. selling and marketing expense for the quarter ending 2024-12-31 was $816.00.
- Bluejay Diagnostics, Inc. selling and marketing expense for the quarter ending 2024-09-30 was $753.00.
- Bluejay Diagnostics, Inc. selling and marketing expense for the quarter ending 2024-06-30 was $305.00, a 99.80% decline year-over-year.
- Bluejay Diagnostics, Inc. selling and marketing expense for the quarter ending 2024-03-31 was $6.42K, a 95.66% decline year-over-year.
- Bluejay Diagnostics, Inc. selling and marketing expense for fiscal 2024 was $8.30K, a 97.07% decline from fiscal 2023.
- Bluejay Diagnostics, Inc. selling and marketing expense for fiscal 2023 was $283.44K, a 37.21% decline from fiscal 2022.
- Bluejay Diagnostics, Inc. selling and marketing expense for fiscal 2022 was $451.42K, a 55.81% increase from fiscal 2021.
- Bluejay Diagnostics, Inc. selling and marketing expense for fiscal 2021 was $289.73K, a 296.77% increase from fiscal 2020.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $816.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.57K derived: sum of 2 quarters · filed 2026-03-06 | $1.87K derived: sum of 3 quarters · filed 2026-03-06 | $8.30K 10-K · filed 2026-03-06 |
| 2024-09-30 | $753.00 10-Q · filed 2025-11-07 | $1.06K derived: sum of 2 quarters · filed 2025-11-07 | $7.48K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $305.00 10-Q · filed 2025-08-07 | $6.73K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $6.42K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $283.44K 10-K · filed 2025-03-31 | |||
| 2023-06-30 | $154.33K 10-Q · filed 2024-08-14 | $302.38K 10-Q · filed 2024-08-14 | $472.65K derived: sum of 3 quarters · filed 2024-08-14 | $618.75K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $148.05K 10-Q · filed 2023-05-11 | $318.32K derived: sum of 2 quarters · filed 2023-05-11 | $464.43K derived: sum of 3 quarters · filed 2023-05-11 | $545.78K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-12-31 | $170.28K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $316.38K derived: sum of 2 quarters · filed 2023-03-20 | $397.74K derived: sum of 3 quarters · filed 2023-08-14 | $451.42K 10-K · filed 2023-03-20 |
| 2022-09-30 | $146.10K 10-Q · filed 2022-11-09 | $227.46K derived: sum of 2 quarters · filed 2023-08-14 | $281.14K 10-Q · filed 2022-11-09 | $381.11K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-06-30 | $81.36K 10-Q · filed 2023-08-14 | $135.04K 10-Q · filed 2023-08-14 | $235.00K derived: sum of 3 quarters · filed 2023-08-14 | $305.41K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $53.69K 10-Q · filed 2023-05-11 | $153.65K derived: sum of 2 quarters · filed 2023-05-11 | $224.06K derived: sum of 3 quarters · filed 2023-05-11 | $274.31K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $99.96K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $170.37K derived: sum of 2 quarters · filed 2023-03-20 | $220.62K derived: sum of 3 quarters · filed 2023-03-20 | $289.73K 10-K · filed 2023-03-20 |
| 2021-09-30 | $70.41K 10-Q · filed 2022-11-09 | $120.66K derived: sum of 2 quarters · filed 2022-11-09 | $189.76K 10-Q · filed 2022-11-09 | $209.21K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $50.25K 10-Q · filed 2022-08-10 | $119.35K 10-Q · filed 2022-08-10 | $138.80K derived: sum of 3 quarters · filed 2022-08-10 | $153.15K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $69.10K 10-Q · filed 2022-05-09 | $88.55K derived: sum of 2 quarters · filed 2022-05-09 | $102.90K derived: sum of 3 quarters · filed 2022-05-09 | |
| 2020-12-31 | $19.45K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $33.80K derived: sum of 2 quarters · filed 2022-03-10 | $73.02K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $14.35K 10-Q · filed 2021-12-16 | $53.57K 10-Q · filed 2021-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |